For young people with Autistic Spectrum Disorder (ASD), everyday settings such as a busy classroom, shopping centre or public transport, can cause anxiety and phobias.
For young people with Autistic Spectrum Disorder (ASD), everyday settings such as a busy classroom, shopping centre or public transport, can cause anxiety and phobias.
The Blue Room is a virtual reality treatment that provides a controlled space for young people to face these scenarios. During the treatment, trained specialists help patients through situations within a personalized virtual reality space.
Many autistic people have difficulty creating scenarios using their imagination, which can make treatment of phobias difficult. Additionally, phobias and anxieties differ greatly from one person to the next. This is where the Blue Room comes in.
We have created over 50 scenarios which we can alter for each patient’s needs. These are used to help patients overcome their anxieties of social interactions, objects or animals. Examples of available scenarios include dogs, wasps/bees, lifts, fear of the dark, flying, school, walking into rooms, getting onto crowded public transport, crossing a bridge or talking to a shop assistant.
The Blue Room is a purpose-built virtual reality space built for people with ASD. Besides the wide range of scenarios it can simulate, it tackles many of the challenges of treating people with ASD. Each scenario can gradually increase both the complexity and noise level, allowing for controlled exposure – which cannot be achieved in real life.
Virtual reality headsets and goggles can distress people with ASD. Instead, Blue Room provides a room-sized space by projecting onto the walls, ceiling and floor. Patients have full control of their movement using a touch tablet, letting them progress at a pace they are comfortable with.
Overwhelming sensory input is a common problem for people with ASD in many everyday situations. The Blue Room provides safe exposure to these situations, as each scenario can be changed to reduce or increase the visual complexity and noise levels of the space.
Controlled trials have shown that 40% of the children treated at the Blue Room showed growth in coping with a real life situation after just 2 weeks. This grew to 45% after 6 months. These results are similar to other methods and the team is focused on how to further increase the rate of positive responses.
In a separate trial, the Blue Room treated eight autistic adults. Each participant completed four 20-minute sessions. After six months, five of the adults reported ongoing improvements related to their phobia.
Blue Room has been developed by a team at Newcastle University, utilising technology developed by Third Eye Technologies. In the UK alone, around 150,000 children are thought to have ASD. The NHS is offering the Blue Room as a treatment method for children with autism aged from 7-17.
Purchase the ILO today to directly support the widespread use of our technology, and ensure a better future for those with ASD.
Our ILO guarantees that when we make money - you make money.
ILO’s are not based on profits, but gross revenue, or all sales without any costs or taxes subtracted, therefore if you buy our ILO you will make money as we make sales.
These projections are provided by us, Neurotech Solutions LTD. If you agree they are realistic and achievable, buy our ILO today.
Commencement Date
Licenses Available
Current Allocation
Total Issued
per license, 10% royalty in year 1
per license, 10% royalty in year 2
per license, 10% royalty in year 3
In addition to paying you a royalty, at the end of the 3rd year Neurotech Solutions LTD can choose to extend the license for another 3 years, or buy the ILO back for cash should Neurotech Solutions LTD conduct a major financing.
ILO Value is the estimated value of your ILO in USD ($). This is calculated using our projected revenue numbers. Therefore if our revenue projections are realistic and achievable, this is a good estimation of the buy out price you should expect at different stages.
THIS AGREEMENT is between Neurotech Solutions LTD (“the Company”), - AND – The Buyer who is the Current License Holder, and who holds this license to promote the companies message to their audience with a view increasing their sales, which will in turn will increase the royalty to all license holders. The Buyer is determined by the Live Ledger held by ILOCX which holds details of licenses issued bought and sold (“the Buyer”).
July 12, 2019
Details of the Licensed Product are described on the Company’s page hosted on the site at www.ILOCX.com
None
Minimum Requirements for Qualification are a confirmed share of the Company’s information and Promotional Message on social media. This can be done on the ILOCX platform. Alternative ways to qualify are at the discretion of the company selling the license.
$40
Under the License Agreement the buyer is entitled to royalty payments once qualified
Each License receives a royalty equal to 10% of the Gross Revenues from the recorded and officially filed revenue, divided by 40,000, the total amount of ILO Units in the Initial License Offering. All royalties will be paid to the Buyer’s wallet on the ILOCX platform within 5 days of payment settlement from the company. These days will be announced prior to release.
This License is for an Initial Term of 3 years at which time the License can be extended by the issuing Company for a further 3 years, (a “Rollover”) and new terms may be set by the company at this time in line with ILOCX exchange rules and guidelines. Alternatively, the Company may offer to buy the License back from the Buyer (“a ‘Buyback”). The Company will give notice of Rollover terms or Buyback Price 90 days before the end of the Initial Term, as outlined in the Buyer Terms and Conditions.
All licenses must be valid and deemed qualified to benefit from the Royalty and the Rollover or Buyback.
This Agreement should be read in conjunction with the License Terms and Conditions, the Company Terms and Conditions, the Buyer Terms and Conditions and the ILOCX Terms of Use which form part of this entire Agreement, as well all ILOCX rules, policies, rulings and procedural requirements (collectively the “ILOCX Terms and Conditions”).
All parties have read and agreed to comply with the ILOCX Terms and Conditions, this Agreement, and any documents included by reference above. These may be amended from time to time and the parties will be notified by email of such amendments. Breach of any of the terms of this agreement may result in termination of this Agreement under the termination procedures outlined in the License Terms and Conditions.
This Agreement shall be governed by the laws of Newcastle Upon Tyne, UK and the parties exclusively submit to the jurisdiction of the Courts of Newcastle Upon Tyne, UK. In the event of any dispute, refer to the terms and conditions for the procedure.
Agreed on behalf of the Company:
The Company confirms its consent to this License Agreement by presenting the ILO for sale on the ILOCX platform.
Agreed on behalf of the Buyer:
The Buyer consents to this agreement by completing their order on ILOCX.
We are pleased to announce the imminent relaunch of the Blue Room on the ILO Exchange now that we can finally commence the initial opening of centres nationally through our UK health partners and, despite the setback caused by the Covid-19 pandemic, Neurotech Solutions Ltd will be paying its first royalty payment of £10 to License holders, representing a 25% return to date on the price paid for their License(s).
Diabetes Actual seeks to restore metabolic wellness through the use of proven therapies for reversing the ravages of diabetes by restoring insulin sensitivity.
TeaCo Biological Supply is on a mission to regenerate and restore the world's depleted soils.
LuxMods has emerged as a new leader in modular housing, with the modular home market is expected to grow to over 114 billion by 2028, and LuxMods projecting over $170 million in revenue in the next 3 years alone.
4D Vision was founded to develop revolutionary green power solutions, tackling the biggest challenges in renewable energy.
